{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:40:10Z","timestamp":1750005610160,"version":"3.41.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>In several health economic analyses of rotavirus vaccines in Japan, all were not cost-effective from the healthcare payer perspective (HPP) but generally cost-effective from the societal perspective (SP). However, few studies have incorporated clinically significant factors of vaccine herd immunity, convulsions with gastroenteritis, encephalopathies, nosocomial infections, death, and intussusception as a vaccine side effect. A cost-utility analysis incorporating these were conducted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We used Bakir\u2019s decision-tree model and data in Japan with 94% coverage rate, 5-year time horizon, and 2% discount. We compared the incremental cost-effectiveness ratio (ICER) with a willingness-to-pay of Japanese Yen (JPY) 5 million from HPP and SP. Scenario 1 examined items based on existing research; scenario 2 additionally examined the above-mentioned items. In scenario 2, break-even prices were determined, and one-way and probabilistic sensitivity analyses were performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In scenario 1, the ICER was JPY 6,057,281 from the HPP and dominant from the SP. In scenario 2, it was JPY 3,713,488 from the HPP. From the HPP in scenario 2, break-even prices were JPY 34,227 for an ICER of JPY 5 million and JPY 17,798 for cost-saving. One-way sensitivity analysis showed ICERs fluctuated widely with ambulatory visits and vaccination costs. In the probabilistic sensitivity analysis, ICERs of 54.8% were less than the willingness-to-pay. In scenario 2, from the SP, vaccines were dominant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>From the HPP in scenario 2, the vaccines were cost-effective. In the sensitivity analyses, ICERs also improved from the HPP over previous studies. Herd immunity for ambulatory visits contributed most to the decline.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002938","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T19:50:57Z","timestamp":1602705057000},"page":"162-168","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Cost-utility Analysis of Rotavirus Vaccines Including the Latest Evidence and Data as of June 2020 in Japan"],"prefix":"10.1097","volume":"40","author":[{"given":"Teruyoshi","family":"Kurosawa","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Teikyo University Mizonokuchi Hospital, Kawasaki City, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Teikyo University Mizonokuchi Hospital, Kawasaki City, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Teikyo University Graduate School of Public Health, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"R1-20250615","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3201\/eid1202.050006","article-title":"Rotavirus and severe childhood diarrhea.","volume":"12","author":"Parashar","year":"2006","journal-title":"Emerg Infect Dis"},{"issue":"suppl 2","key":"R2-20250615","first-page":"S32","article-title":"Options for the prevention of rotavirus disease other than vaccination.","volume":"46","author":"Mrukowicz","year":"2008","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"suppl 5","key":"R3-20250615","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1469-0691.2012.03981.x","article-title":"Rotavirus vaccination: a concise review.","volume":"18","author":"Vesikari","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"R6-20250615","doi-asserted-by":"crossref","first-page":"277","DOI":"10.7883\/yoken.64.277","article-title":"Cost-effectiveness analysis of a universal rotavirus immunization program in Japan.","volume":"64","author":"Sato","year":"2011","journal-title":"Jpn J Infect Dis"},{"key":"R7-20250615","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3111\/13696998.2013.831869","article-title":"Cost-effectiveness of a pentavalent rotavirus vaccine in Japan.","volume":"16","author":"Itzler","year":"2013","journal-title":"J Med Econ"},{"key":"R8-20250615","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/21645515.2016.1245252","article-title":"Economic evaluation of routine infant rotavirus immunisation program in Japan.","volume":"13","author":"Hoshi","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"R9-20250615","first-page":"239","article-title":"Cost-effectiveness of rotavirus vaccination using direct non-medical costs and opportunity costs estimated from the internet survey data.","volume":"41","author":"Nakagomi","year":"2013","journal-title":"Clin Virol"},{"key":"R12-20250615","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.vaccine.2012.11.071","article-title":"Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model.","volume":"31","author":"Bakir","year":"2013","journal-title":"Vaccine"},{"key":"R14-20250615","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2431-13-83","article-title":"The burden of rotavirus gastroenteritis and hospital-acquired rotavirus gastroenteritis among children aged less than 6 years in Japan: a retrospective, multicenter epidemiological survey.","volume":"13","author":"Tajiri","year":"2013","journal-title":"BMC Pediatr"},{"key":"R15-20250615","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3111\/13696990802321047","article-title":"Estimating utility scores in young children with acute rotavirus gastroenteritis in the UK.","volume":"11","author":"Martin","year":"2008","journal-title":"J Med Econ"},{"key":"R16-20250615","article-title":"Estimating effectiveness of rotavirus vaccines including herd immunity in Japan.","author":"Kurosawa","year":"2020","journal-title":"Journal of the Kawasaki City Pediatric Society"},{"journal-title":"Research Report on Research Project for Overcoming Intractable Diseases","article-title":"Nationwide survey of acute encephalopathy.","author":"Mizuguchi","key":"R17-20250615"},{"journal-title":"Intractable Disease Policy Research Project","article-title":"Nationwide survey of acute encephalopathy (2nd).","author":"Mizuguchi","key":"R18-20250615"},{"key":"R19-20250615","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1016\/j.vaccine.2012.03.030","article-title":"Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population.","volume":"30","author":"Phua","year":"2012","journal-title":"Vaccine"},{"key":"R20-20250615","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jpeds.2016.01.042","article-title":"Sustained effectiveness of monovalent and pentavalent rotavirus vaccines in children.","volume":"172","author":"Immergluck","year":"2016","journal-title":"J Pediatr"},{"key":"R21-20250615","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/ciu746","article-title":"Does preventing rotavirus infections through vaccination also protect against naturally occurring intussusception over time?","volume":"60","author":"Payne","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R23-20250615","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hec.1481","article-title":"International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?","volume":"19","author":"Shiroiwa","year":"2010","journal-title":"Health Econ"},{"key":"R24-20250615","doi-asserted-by":"crossref","first-page":"6335","DOI":"10.1016\/j.vaccine.2011.05.017","article-title":"Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life.","volume":"29","author":"Kawamura","year":"2011","journal-title":"Vaccine"},{"key":"R25-20250615","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.4161\/hv.24846","article-title":"Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial.","volume":"9","author":"Iwata","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"R26-20250615","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.vaccine.2009.04.030","article-title":"Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination.","volume":"27","author":"Shim","year":"2009","journal-title":"Vaccine"},{"key":"R27-20250615","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/1471-2458-11-462","article-title":"Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model.","volume":"11","author":"Rozenbaum","year":"2011","journal-title":"BMC Public Health"},{"key":"R28-20250615","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2334-13-54","article-title":"An update of \u201cCost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model.\u201d","volume":"13","author":"Tu","year":"2013","journal-title":"BMC Infect Dis"},{"key":"R29-20250615","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.1016\/j.vaccine.2012.09.025","article-title":"The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales.","volume":"30","author":"Atkins","year":"2012","journal-title":"Vaccine"},{"key":"R30-20250615","doi-asserted-by":"crossref","first-page":"e53864","DOI":"10.1371\/journal.pone.0053864","article-title":"Impact of rotavirus vaccination on hospitalisations in Belgium: comparing model predictions with observed data.","volume":"8","author":"Standaert","year":"2013","journal-title":"PLoS One"},{"issue":"suppl 1","key":"R31-20250615","doi-asserted-by":"crossref","first-page":"A126","DOI":"10.1016\/j.vaccine.2014.12.074","article-title":"Cost-effectiveness analysis of rotavirus vaccination in Argentina.","volume":"33","author":"Urue\u00f1a","year":"2015","journal-title":"Vaccine"},{"key":"R32-20250615","doi-asserted-by":"crossref","first-page":"7601","DOI":"10.1016\/j.vaccine.2012.10.034","article-title":"Effectiveness and cost-effectiveness of pediatric rotavirus vaccination in British Columbia: a model-based evaluation.","volume":"30","author":"Fisman","year":"2012","journal-title":"Vaccine"},{"key":"R33-20250615","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ije\/dyz028","article-title":"Update on the global epidemiology of intussusception: a systematic review of incidence rates, age distributions and case-fatality ratios among children aged <5 years, before the introduction of rotavirus vaccination.","volume":"48","author":"Clark","year":"2019","journal-title":"Int J Epidemiol"},{"key":"R35-20250615","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.vaccine.2010.01.014","article-title":"Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?","volume":"28","author":"Mangen","year":"2010","journal-title":"Vaccine"},{"key":"R36-20250615","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.1016\/j.vaccine.2009.08.030","article-title":"The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe.","volume":"27","author":"Jit","year":"2009","journal-title":"Vaccine"},{"key":"R37-20250615","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/01.inf.0000197563.03895.91","article-title":"Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease.","volume":"25","author":"Olivier","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"R38-20250615","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.vaccine.2004.08.017","article-title":"Rotavirus vaccines and the prevention of hospital-acquired diarrhea in children.","volume":"22","author":"Thea","year":"2004","journal-title":"Vaccine"},{"key":"R39-20250615","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.4161\/hv.24253","article-title":"A critical literature review of health economic evaluations of rotavirus vaccination.","volume":"9","author":"Aball\u00e9a","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"R40-20250615","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4091\/iken.16.157","article-title":"Research for willingness to pay for one QALY gain.","volume":"16","author":"Ohkusa","year":"2006","journal-title":"J Health Care Soc"},{"key":"R41-20250615","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJM199610033351404","article-title":"Rotavirus infection in infants as protection against subsequent infections.","volume":"335","author":"Vel\u00e1zquez","year":"1996","journal-title":"N Engl J Med"},{"key":"R42-20250615","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/infdis\/162.4.810","article-title":"Molecular epidemiology of rotavirus in children attending day care centers in Houston.","volume":"162","author":"O\u2019Ryan","year":"1990","journal-title":"J Infect Dis"},{"key":"R43-20250615","doi-asserted-by":"crossref","first-page":"563","DOI":"10.4161\/hv.7.5.15406","article-title":"Efficacy of the pentavalent rotavirus vaccine, RotaTeq\u00ae (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen).","volume":"7","author":"Dennehy","year":"2011","journal-title":"Hum Vaccin"},{"key":"R44-20250615","first-page":"1122","article-title":"Effectiveness of rotavirus vaccines for decrease of rotavirus gastroenteritis in a pediatric outpatient clinic, analyzed by Vesikari Score.","volume":"123","author":"Nakata","year":"2019","journal-title":"J Jpn Pediatr Soc"},{"key":"R45-20250615","first-page":"173","article-title":"Clinical features of rotavirus acute gastroenteritis in children: influence and efficacy of vaccination and comparison with other acute gastroenteritis.","volume":"42","author":"Kurosawa","year":"2019","journal-title":"Teikyo Medical Journal"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:05:17Z","timestamp":1750003517000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002938","relation":{},"ISSN":["0891-3668"],"issn-type":[{"type":"print","value":"0891-3668"}],"subject":[],"published":{"date-parts":[[2020,10,12]]}}}